Spectrophotometric Determination of Apixaban in Bulk Drug and Oral Dosage Formulation

Authors

  • Deepshikha Sharma  Department of Chemistry, Sheth L.H. Science College, (Scholars of Gujarat University, Ahmedabad) Mansa, India
  • Vikramsinh R. Chauhan  Department of Chemistry, Sheth L.H. Science College, Mansa, Gujarat University, Ahmedabad, India.
  • Kartik B. Vyas  Department of Chemistry, Sheth L.H. Science College, Mansa, Gujarat University, Ahmedabad, India.

DOI:

https://doi.org/10.32628/IJSRST207263

Keywords:

Apixaban, Spectrophotometric, UV-Vis, Atrial fibrillation, DOAC

Abstract

A simple, rapid, cost effective and extractive UV-Vis spectrophotometric method has been developed for the determination of Apixaban (AP) in bulk drug and pharmaceutical formulation. It was based on UV-Vis spectrophotometric measurements in which the drug reacts chromogenic reagent (N-(1-napthyl) ethylene diamine dihydrochloride solution) in acidic medium and give stable pale yellow colored complex which exhibits absorption maximum at 680 nm. Beer’s law was obeyed in the concentration range of 5 - 50 μg /ml. This method was tested and validated for various parameters according to ICH guidelines. The proposed method was successfully applied for the determination of AP in oral formulation. The results demonstrated that the procedure is accurate, precise and reproducible (relative standard deviation < 2 %). As it is simple, cheap and less time consuming, it can be suitably applied for the estimation of LA in dosage forms in quality control labs.

References

  1. P. A. Wolf, R. D. Abbott, and W. B. Kannel, “Atrial fibrillation as an independent risk factor for stroke: the Framingham study,” Stroke, vol. 22, no. 8, pp. 983–988, 1991.
  2. L. Friberg, M. Rosenqvist, and G. Y. H. Lip, “Net clinical benefit of warfarin in patients with atrial fibrillation,” Circulation, vol. 125, no. 19, pp. 2298–2307, 2012.
  3. H. A. van den Ham, O. H. Klungel, D. E. Singer,H. G. M. Leufkens, and T. P. van Staa, “Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation,” Journal of the American College of Cardiology, vol. 66, no. 17, pp. 1851–1859, 2015.
  4. T. P. van Staa, E. Setakis, G. L. Di Tanna, D. A. Lane, and G. Y. H. Lip, “A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice,” Journal of 5rombosis and Haemostasis, vol. 9, no. 1, pp. 39–48, 2011.
  5. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009.
  6. R. P. Giugliano, C. T. Ruff, E. Braunwald et al., “Edoxaban versus warfarin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 369, no. 22, pp. 2093–2104, 2013.
  7. C. B. Granger, J. H. Alexander, J. J. V. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” New England Journal of Medicine, vol. 365, no. 11, pp. 981– 992, 2011.
  8. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011.
  9. Cheng JW, Barillari G. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. J Clin Pharm Ther. 2014;39:118–135.
  10. Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther. 2014;8: 789–798.
  11. Fenger-Eriksen C, Münster AM, Grove EL. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiol Scand. 2014;58:651–659.
  12. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–328.
  13. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24–S33.
  14. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52(2):69-82. DOI: 10.1007/s40262- 012-0030-9.
  15. European Medicine Agency, Eliquis: Summary of Product Characteristics. Available at http://www.ema.europa. eu/ docs/en_GB/document_library/EPAR_ Product_ Information / human/002148/WC500107728. pdf. Accessed October 23rd, 2014.
  16. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug29;369(9):799-808. DOI: 10.1056/NEJMoa1302507
  17. Cheng JW, Barillari G. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management:evidence and unanswered questions. J Clin Pharm Ther.2014;39(2):118-35. DOI: 10.1111/jcpt.12122
  18. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013 Aug 8;8:CD008980. DOI: 10.1002/14651858.CD008980.pub2
  19. Bauer KA. Pros and cons of new oral anticoagulants. Management of Thromboembolic Disease. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. DOI: 10.1182/asheducation-2013.1.464
  20. 8. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. Anesthesiology. 2013 Jun;118(6):1466-74. DOI: 10.1097/ ALN.0b013e318289bcba
  21. Vílchez JA, Gallego P, Lip GYH. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf 2014;5(1):8–20. DOI: 10.1177/2042098613507945
  22. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major bleeding complicationsand emergency surgery in patients on longterm treatment with direct oral anticoagulants, thrombinor factor-Xa inhibitors: proposals of the workinggroup on perioperative haemostasis (GIHP) – March 2013. Arch Cardiovasc Dis. 2013;106(6-7):382-93.DOI: 10.1016/j.acvd.2013.04.009
  23. Dincq AS, Lessire S, Douxfils J, Dogné JM, Gourdin M, Mullier F. Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. Biomed Res Int. 2014;2014:385014. DOI:10.1155/2014/385014
  24. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013 Jun;35(3):262-8. DOI: 10.1111/ ijlh.12065
  25. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013 Nov;76(5):776-86. DOI: 10.1111/bcp.12106
  26. Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013 Dec 6;5:177-84. DOI: 10.2147/CPAA.S51981
  27. Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry:application to pharmacokinetic study. J Pharm Biomed Anal. 2013 May 5;78-79:150-3. DOI: 10.1016/j.jpba.2013.02.007

International Journal of Scientific Research in Science and Technology

Downloads

Published

2019-05-20

Issue

Volume 6, Issue 3, May-June-2019

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Deepshikha Sharma, Vikramsinh R. Chauhan, Kartik B. Vyas "Spectrophotometric Determination of Apixaban in Bulk Drug and Oral Dosage Formulation" International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011,Volume 6, Issue 3, pp.377-385, May-June-2019. Available at doi : https://doi.org/10.32628/IJSRST207263